News

SORT BY YEAR
31 July, 2018

Ally Bridge Portfolio News – Innovent Announced $150 Million Series E

ChinaBio Today Report / Apr 29, 2018 Innovent of Suzhou announced its series E financing of $150 million. Capital Group Private Markets (CGPM) is leading this investment with $90 million, followed by other investors including Cormorant Asset Management, Rock Springs Capital, Ally Bridge Group as well as return backers Hillhouse, Legend Capital, Lilly Asia Ventures […]

Read More
31 July, 2018

Ally Bridge Portfolio News – Chinese sovereign wealth fund backs LinkDoc’s $151m Series D

Deal Street Asia / Jul 5, 2018 China Investment Corporation (CIC), a sovereign wealth fund has participated in a RMB1 billion (US$151 million) series D round in Beijing-based oncology, big data firm LinkDoc Technology Ltd. Following in the footsteps of retail and education, healthcare firms in China have been on the VC radar and have attracted […]

Read More
31 July, 2018

Ally Bridge Group News: BioCentury Report – CHINA COMES TO EUROPE

CHINA COMES TO EUROPE CHINESE INVESTORS ARE LOOKING TO EUROPE FOR INNOVATION AT ATTRACTIVE PRICES BY STEPHEN HANSEN, ASSOCIATE EDITOR The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of investors […]

Read More
31 July, 2018

BioCentury – Ally Bridge invests in Tasly Biopharmaceuticals

Tasly Biopharmaceuticals Co. Ltd. (Shanghai, China) said Wednesday it issued 75.7 million new shares, representing about 7% of the company, as it prepares for a possible IPO. The investors, which include Ally Bridge LB Healthcare Fund, Pudong Technology (Cayman) Co. Ltd., BOCOM International Holdings Co. Ltd. (HKSE:3329) and Grand Riches Jiaheng Investment Holdings Ltd., contributed […]

Read More
31 July, 2018

Ally Bridge Portfolio News – ABG Among Cornerstone Investors in US$933mn BeiGene Secondary Hong Kong Listing

Bloomberg / July 27, 2018, 10:48 PM GMT+8 BeiGene Ltd., a cancer drug developer, is seeking as much as HK$7.32 billion ($933 million) through a secondary listing in Hong Kong after debuting in New York in 2016. The biotech firm is offering 65.6 million shares at HK$94.40 to HK$111.60 apiece, according to a prospectus released […]

Read More
31 July, 2018

Ally Bridge Portfolio News – I-Mab Successfully Raised USD 220 Million in Series C Funding

SHANGHAI, June 29, 2018 /PRNewswire/ — I-Mab Biopharma, a company focusing on innovative Biologics in therapeutic areas of immuno-oncology and immuno-inflammation, announced the completion of Series C financing for USD 220 million, representing one of the largest amounts ever raised in Series C by an innovative biotech company in China. This round of funding was […]

Read More
12 July, 2018

Ally Bridge Group News: Endpoint News – 12 top China VCs you need to know who are making a transpacific splash

Money is rushing into biotech at breakneck speed this year, and one part of the globe is accounting for much of the uptick: China. VC deals were teeming with Chinese investors in the first half of the year, with China-based firms participating in US biotech investment rounds worth $5.1billion, according to data from PitchBook. For […]

Read More
4 June, 2018

Ally Bridge Portfolio News – Ally Bridge Group Expands Early-stage Cancer Solution Portfolio with Investment in Quantum Surgical

HONG KONG and MONTPELLIER, France, June 3, 2018 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading cross-border life science investment group, has completed a Series A investment, as the first part of a total of $50 million raise, in Quantum Surgical, an innovative surgical robotics company in France. Quantum Surgical is developing next-generation robotic solutions […]

Read More
23 May, 2018

Ally Bridge Portfolio News – Ally Bridge Group Leads GRAIL’s $300 Million Series C Financing

HONG KONG, May 21, 2018 /PRNewswire/ — Ally Bridge Group, a global life science-focused investment group, today announced that it has led a $300 million financing completed for GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured. “We are very impressed with the scientific, clinical, and software […]

Read More
23 May, 2018

Ally Bridge Portfolio News – GRAIL Announces $300 Million Raised in Oversubscribed Series C Financing

MENLO PARK, Calif. & HONG KONG–(BUSINESS WIRE) — GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced it has raised USD$300 million in an oversubscribed Series C financing. The financing is led by Ally Bridge Group, co-led by Hillhouse Capital Group and 6 Dimensions Capital, […]

Read More